

21<sup>st</sup> August, 2021

To,  
The Deputy Manager  
Department of Corporate Services,  
BSE Ltd, PJ Towers  
Dalal Street, Mumbai-01  
Scrip Code: 511509

Dear Sir/Madam,

**Sub: Service Capability Expansion by Debt Raise-Reg.**  
**Ref: Regulation 30 of SEBI (LODR) Regulations, 2015.**

We wish to inform you that the Company in line with the long term strategy of the company to become a full service Contract Research Organization and to serve all the needs of Large Pharma & Bio Pharma companies for their Drug Discovery needs, Vivo Bio is investing on new Equipment, Facility development and Process-validations. The company has raised a debt of Rs.18.17 crores towards this end from Canara Bank to develop “**End to End Drug Discovery platform**” to enable Global Pharma and Bio-Pharma companies to partner with Vivo Bio for Joint Drug Discovery. Vivo Bio is now capable of providing end- to-end analytical, bioanalytical, scientific and regulatory capabilities on a range of new molecules, in particular on high demand Oncology molecules. Involving various in-vitro and in-vivo models. Vivo Bio is already serving a plethora of main stream Pharma & Bio-Pharma companies in India and is uniquely placed in the domains of Pharmacology models in particular Oncology models, Transgenic Animal Models, Specific Pathogen Free Animal Breeding & Supply & Laboratory Animal Diagnostics.

The newly added Agro-chem services of Vivo include capabilities on all acute / chronic studies, physio-chemical studies, multi batch analysis, residual studies and ecotoxicology studies that are required for various Indian and Global Agro chemical companies for regulatory submission.

These new Drug Discovery and Agri-chem services capabilities will place Vivo in the league of select few full service CRO companies globally. It is expected the new services would generate additional revenues starting from FY 22-23, with good operating margins.

The details as required under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9<sup>th</sup> September, 2015 is given in **Annexure-1**.



Further in accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code of conduct of prevention of insider trading, the trading window for dealing in the securities of the Company for all Directors, promoters, designated persons and insiders of the Company and their immediate relatives shall remain closed till Tuesday i.e. 24<sup>th</sup> August, 2021.

A copy of this letter is being hosted on the Company's website at [www.vivobio.com](http://www.vivobio.com).

We request you to take the above information on record.

Thanking you,

Yours faithfully,

**For Vivo Bio Tech Ltd**



**A.Karthik**  
Company Secretary



**Annexure-1**

**Adoption of new line(s) of business:**

Sl. No	Particulars	Details
a)	Industry or area to which the new line of business belongs to;	Drug Discovery services involving In-vitro ADME, In-vivo DMPK and Bio-analytical services and Agrochem services.
b)	Expected benefits;	1) This will make Vivo full service CRO. 2) Help partnering with major Indian and Global discovery companies involved in Drug research. 3) Position Vivo bio in one of the top five Drug discovery companies in India. 4) Increase in business. 5) Brand value enhancement.
c)	Estimated amount to be invested.	Rs 18.17 Cr.

*A. Kauthik*

